One platform connecting startups, corporations, research institutions, regions and investors
Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
EDTECH: LEVERAGING AI-POWERED TECHNOLOGIES TO TRANSFORM THE LEARNING EXPERIENCE
1. Technology overview
Eyenuk, Inc. is an AI digital health company with a San Francisco address on its site, focused on screening every eye for diabetic retinopathy, glaucoma, age-related macular degeneration and other disease.
Its EyeArt system grades retinal images from multiple fundus camera brands in under 30 seconds without ophthalmologist review, and is offered as Screening, Triage and Monitoring solutions. It integrates with EHRs to pull orders and return reports. The page claims 500K+ patients scanned and lists U.S., Canadian and German clinics among customers.
2. Highlighted features & specifications
- Autonomous DR screening: Grades retinal images without ophthalmologist review.
- Multi-disease detection: Covers diabetic retinopathy, AMD and glaucomatous optic nerve damage.
- Triage and monitoring: Prioritizes patients and tracks pathology trends over time.
- Multi-camera support: Compatible with retinal cameras from major manufacturers.
- EHR integration: Pulls orders and syncs reports to the patient record.
- Analytics: Provides on-demand dashboards on screening volumes.
3. Potential application
Endocrinology clinics in Vietnam can screen diabetic patients in the same visit. Provincial hospitals can triage referrals to eye centers. Health-check chains can add retinal screening to annual packages.
4. Benefits
Autonomous grading in under 30 seconds removes the need for specialist reading at the point of screening.
Works with several retinal camera brands, protecting existing hardware investment.
EHR integration returns diagnostic reports to the patient record.
Regulatory coverage includes FDA 510(k), EU MDR Class IIb CE mark, SOC 2 Type 2 and ISO 13485.
5. Market trends & opportunities
Vietnam and Southeast Asia have rapidly growing diabetic populations and few ophthalmologists, so primary-care screening with autonomous AI is attracting health systems. National deployments such as Norway in 2025 show public payers adopting the approach.
6. Other information
Address: 2261 Market St, San Francisco, CA. CEO Gaurav Agarwal and Chairman Mads Dall appointed January 2025. EyeArt v3.0 deployed via the Norwegian procurement run by Sykehusinnkjop HF.
